| dc.contributor.author | Gurses, N | |
| dc.contributor.author | Uysal, S | |
| dc.contributor.author | Cetinkaya, F | |
| dc.contributor.author | Islek, I | |
| dc.contributor.author | Kalayci, Ag | |
| dc.date.accessioned | 2020-06-21T11:31:50Z | |
| dc.date.available | 2020-06-21T11:31:50Z | |
| dc.date.issued | 1995 | |
| dc.identifier.issn | 0036-5548 | |
| dc.identifier.uri | https://doi.org/10.3109/00365549509019016 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/9900 | |
| dc.description | WOS: A1995RK10500010 | en_US |
| dc.description | PubMed: 8539548 | en_US |
| dc.description.abstract | Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Scandinavian University Press | en_US |
| dc.relation.isversionof | 10.3109/00365549509019016 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Intravenous Immunoglobulin Treatment in Children With Guillain-Barre-Syndrome | en_US |
| dc.type | article | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 27 | en_US |
| dc.identifier.issue | 3 | en_US |
| dc.identifier.startpage | 241 | en_US |
| dc.identifier.endpage | 243 | en_US |
| dc.relation.journal | Scandinavian Journal of Infectious Diseases | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
